A Phase 2, Open-label, Study Evaluating Safety and Efficacy of the Loncastuximab in Relapsed/Refractory Marginal Zone Lymphoma
Overview
- Phase
- Phase 2
- Intervention
- Loncastuximab tesirine 150 µg/Kg
- Conditions
- Marginal Zone Lymphoma
- Sponsor
- University of Miami
- Enrollment
- 50
- Locations
- 4
- Primary Endpoint
- Complete Response (CR) rate of Loncastuximab tesirine in relapsed/refractory at 6 months
- Status
- Recruiting
- Last Updated
- 7 months ago
Overview
Brief Summary
The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects (good and bad) that loncastuximab tesirine has on the participant and the participant's condition.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Men and women, aged 18 years or older.
- •Histologically confirmed MZL, including extranodal, nodal, and splenic subtypes.
- •Previously received 1 or more lines of systemic therapy, including at least 1 anti-CD20 antibody (cluster of differentiation antigen 20) (either as monotherapy or in combination as chemoimmunotherapy), with documented progression or documented failure to achieve CR or PR after the most recent systemic treatment regimen. Subjects with H. pylori-positive gastric extranodal MZL who received an initial treatment with currently accepted antibiotics may be considered eligible if, after antibiotic regimen, subject has histologically confirmed MZL and was subsequently treated with at least 1 line of systemic therapy.
- •Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ≥ 1 lesion that measures \> 1.5 cm in the LDi and ≥ 1.0 cm in the longest perpendicular diameter as assessed by CT or MRI per response criteria for lymphomas.68 Imaging must be conducted within 6 weeks prior to the start of therapy.
- •Subjects with splenic MZL who do not meet the radiographically measurable disease criteria described herein are eligible for participation provided that bone marrow infiltration of MZL is histologically confirmed.
- •Subjects with skin EMZL (extranodal marginal zone lymphoma) who do not meet the radiographically measurable disease criteria described herein are eligible for participation provided that skin lesion measures ≥ 1.5 cm in diameter by tape measure and is documented by photo or there are multiple skin lesions measuring \>1cm in diameter on the body that cannot be incorporated in one radiation field and at least one of them is histologically confirmed as MZL.
- •Subjects with gastric extranodal MZL histologically confirmed and need therapy but do not have measurable disease and in which response to treatment can be assess by multiple random gastric biopsies.
- •Subjects with conjunctival EMZL who do not meet the radiographically measurable disease criteria described herein are eligible for participation provided that conjunctival lesion measures ≥ 1 cm in diameter by tape measure and is documented by photo or there are multiple conjunctival lesions measuring together \>1 5cm that cannot be treated by radiation because of previous radiation therapy, contraindications to radiation and patient refusal to receive radiation therapy. At least one of these lesions needs be histologically confirmed as MZL.
- •Subjects must be willing to provide a lymph node or tissue biopsy from the most recent available archival tissue or undergo an incisional or excisional lymph node or tissue biopsy.
- •a. Subjects with splenic MZL who do not have a tumor to biopsy or an archival tumor tissue sample are eligible for participation provided subject is willing to undergo a bone marrow biopsy or provide an archival bone marrow biopsy that was obtained before the date of the first dose of study treatment; bone marrow sample must show histologically confirmed infiltration of MZL.
Exclusion Criteria
- •Evidence of DLBCL transformation. a. Subjects with presumptive evidence of transformation based on clinical assessment of factors such as, but not limited to, increasing lactate dehydrogenase, rapidly worsening disease, or frequent B-symptoms, must be ruled out for a transformation to a more aggressive disease, such as DLBCL.
- •History of central nervous system lymphoma (either primary or metastatic) or leptomeningeal disease.
- •Concurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, investigational therapy, or tumor embolization).
- •Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of the first dose of study treatment.
- •Active graft versus host disease.
- •Receipt of anticancer medications or investigational drugs within the following intervals before the date of the first dose of study treatment:
- •\< 10 weeks from completion of any radio- or toxin-immunoconjugates.
- •\< 4 weeks for immunotherapy
- •\<. 3 weeks for radiotherapy.
- •\< 2 weeks for any investigational agent or other anticancer medications.
Arms & Interventions
Loncastuximab tesirine Cycles 1-6
Patients will be treated with loncastuximab tesirine for a total of 6 cycles on Day 1 (+/-3) of each 21 day (3 week) cycle. The total duration of treatment is approximately 18 weeks (4.5 months)
Intervention: Loncastuximab tesirine 150 µg/Kg
Loncastuximab tesirine Cycles 1-6
Patients will be treated with loncastuximab tesirine for a total of 6 cycles on Day 1 (+/-3) of each 21 day (3 week) cycle. The total duration of treatment is approximately 18 weeks (4.5 months)
Intervention: Loncastuximab tesirine 75µg/Kg
Outcomes
Primary Outcomes
Complete Response (CR) rate of Loncastuximab tesirine in relapsed/refractory at 6 months
Time Frame: 6 months.
CR rate is defined as the Complete Response (CR)/n, where n is the number of participants. The proportion of patients with best overall response of complete response (CR), per Cheson criteria if disease is not PET (Positron emission tomography)-avid in initial screening and by revised Lugano criteria if screening PET-CT demonstrated PET-avid disease.CR will be defined by a Deauville score of ≤ 3.
Complete Response (CR) rate of Loncastuximab tesirine in relapsed/refractory at 12 months
Time Frame: 12 months.
CR rate is defined as the Complete Response (CR)/n, where n is the number of participants. The proportion of patients with best overall response of complete response (CR), per Cheson criteria if disease is not PET-avid in initial screening and by revised Lugano criteria if screening PET-CT demonstrated PET-avid disease.CR will be defined by a Deauville score of ≤ 3.
Secondary Outcomes
- Partial Response rate at 6 months(6 months)
- Partial Response rate at 12 months(12 months)
- Overall response rate (ORR) at 6 months(6 months)
- Overall response rate (ORR) at 12 months(12 months)
- Overall survival (OS)(2 years)
- Progression-free survival (PFS)(2 years)
- Duration of Response (DOR)(2 years)
- Number of Treatment Related Toxicities(7 months)